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Introduction
Cervical cancer is the second most common type of cancer found in women worldwide. It is the leading form of cancer death in most developing countries (Richart, 1995) . With the advent of strong screening protocols which center on the use ofthe Papanicolaou (Pap smear) test, the cervical cancer death rate in comparison to other cancer deaths in the United States has dropped from over 30% in 1930 to less than 8% in 1994 (Cancer Statistics, 1998 . Similar drops have been seen in other developed countries where the Pap smear is readily available.
Since the development ofthe Pap smear in the 1940's, screening has centered on the use ofthe Pap smear for identification of abnormal pre-invasive cells, known as dysplasia, which are the precursor cells to cervical cancer. Where
Pap smear screening has been properly implemented, cervical cancer death rates have dropped 50 to 70% (Cuzick, 1998) . However, in a retrospective review of 312 labs, Montes, Cibas, DiNisco, and Lee (1999) found that false-negative Pap smears in women with subsequent pathology were identified in 19.7% of the cases reviewed.
Despite formal national screening programs, over 12,000 women in the United States were diagnosed with cancer ofthe cervix in 1998, and 4,800 women died ofthe disease (Cancer Statistics, 1998; Canavan, 2000) . Many women throughout the world and in underserved regions ofthe United States do not have adequate access to the Pap smear technology, and it is not a perfect diagnostic tool for those with access. As long as women continue to die needlessly of cervical cancer, more comprehensive and accessible screening methods must be explored.
Because the Pap smear is a screening tool, rather than a diagnostic tool, further studies must be done to identify the actual nature of discovered abnormalities. Of particular concern is the classification of atypical squamous cells of undetermined significance (ASCUS). This cytological abnormality may simply indicate inflammation, or it may be the first indicator of serious pathology (Apgar & Botzman, 1999) . Because ofthe potential for underlying malignancy, many experts recommend following all ASCUS results with a colposcopy. This approach is often impractical and expensive, as many ofthese early irregular smears are benign (Jones, 1995) . Other approaches to dealing with minor Pap abnormalities include serial repeat Pap smears and testing for the human papillomavirus (HPV), the virus that has been implicated in the evolution of cervical cancer.
Although a variety of factors may cause cervical dysplasia, the primary risk of dysplasia advancing to cervical cancer is human papillomavirus (Kjellberg et a!., 1998) . Van Muyden et aI., (1999) identified HPV in 100% oftheir study population ofwomen with invasive cervical cancer. However, Tabrizi et aI., Most cervical dysplasia occurs in the area ofthe squamocolumnar junction ofthe cervix, an area ofactive squamous cell proliferation. Until puberty, this junction is located on the exposed vaginal portion ofthe cervix and is relatively stable. At puberty, with the accompanying increase in estrogen, the squamous margin encroaches on the single-layered, mucous-secreting epithelium--the columnar epithelium--forming an area ofmetaplasia known as the transformation zone (MacKay, 1999) . In young women and in women on oral contraceptives, this transformation zone is visible surrounding the cervical os and is called ectopy. Ectopy recedes into the endocervical canal with age and with the onset of sexual intercourse (Celum, Wilch, Fennell, & St~ 1998) . Dysplasia is most commonly identified within the transformation zone, thus requiring that cell samples be collected from this area when a Pap smear is obtained.
As noted above, various types of human papillomavirus have been identified as the cause of cervical cancer (Van Muyden et aI., 1999) . Studies indicate that specific HPV types infect the squamous epithelium of the cervix. A number identifies each type ofHPV. Human papillomavirus DNA can be identified in more than 80% of women with biopsy-confirmed SIL, with HPV types 6 and 11 predominating in low-grade SIL. High-grade lesions are most frequently associated with type 16. (Park, Fujiwara, & Wright, 1995) . The HPV DNA incorporates itself into the cellular DNA, activating oncogenes and suppressing the host cell's immune response. Cervical cells are particlLlarly prone to this type of damage during puberty and pregnancy, when the high levels of estrogen are promoting rapid change (Cothran & White, 1995) . The cervix of women who use oral contraceptives is also vulnerable, as the constant infusion of estrogen may prevent the natural recession ofthe ectopy into the cervical canal (Kruger-Kjaer et aI., 1998).
Papillomaviruses are epithelialtrophic, often causing focal epithelial proliferation, commonly known as warts. More than 70 different types of human papillomaviruses have now been identified (Schiffinan & Brinton, 1995) . These variations, although similarly structured, are anatomically specific, with lesions always located in the same epithelial region and with a consistency in the type of lesion that they produce. Research has identified 23 different types ofHPV that infect the female and male anogenital tract. These 23 types are thus passed sexually. These various HPV types are associated with a range of anogenital diseases, from the common genital wart, Condyloma acuminata, to invasive squamous cell carcinoma (Park et aI, 1995) .
Human papillomaviruses associated with the anogenital region include HPV 6, 11, 16, 18, 30, 31, 33, 35, 39, 40, 42-45, 51-58, and 61 (van Muyden et aI., 1999) . These HPV types are also classified according to their oncogenic risk. All sexually active women are at risk for HPV (Reed et aI., 1993) . HPV is the single most common sexually transmitted disease, with detection rates as high as 65% of the general population (Adam et aI., 2000) . HPV peak prevalence occurs in women between 16 and 25 years of age. The prevalence rate drops sharply in women over the age of 30, possibly because of immunologic clearance or suppression of existing infection, or because of less exposure to new HPV types, as women in this older age category typically have fewer new sexual partners (Schiffinan and Brinton, 1995) . Women over 30 may also have a maturational protection, as the vulnerable transformation zone regresses on the face ofthe cervix as women age. HPV levels remain high in women with highgrade lesions. Adam et aI., (2000) found that 38% ofHPV-positive women aged 35 to 39 have high-grade SIL, while only 13.4% ofthose subjects less than 19 years old had similar results. HPV infection and low-grade SIL are usually diagnosed in women in their late teens and early twenties, high-grade SIL in 25 to 35 year-olds, and invasive cervical cancer after the age of35. On average, approximately 15% ofHPV positive cases will progress to high-grade SIL or carcinoma in situ within nine years (Daley, 1998) .
Since most HPV infections disappear within months ofthe initial diagnosis, other factors must also playa role in its potential advancement to cervical cancer. High-oncogenic type HPV is the single most predictive co-factor for cancer progression (Schiffman and Brinton, 1995; Adam et aI., 2000) . High levels ofHPV and the length oftime since the initial infection are also linked to higher-grade lesions. A higher degree of dysplasia is often seen with a longer duration of infection. Immune-compromised women have a much greater likelihood of developing progressive SIL. In a study oflIlV-positive women with no documented cervical disease, Ellerbrock et aI., (2000) diagnosed dysplasia in 20% of the study participants within three years oftheir lIIV diagnosis. Invasive cervical cancer is a definitive diagnosis for AIDS in women who are lIIV positive (Hollander & Katz, 1999) .
Other risks associated with the sexually transmitted nature ofHPV include women who have known their current sexual partner less than 24 months, women with multiple sexual partners or non-monogamous partners, and women who began sexual activity at a younger age (Reed et aI., 1993). Svare et aI., (1998) compared the HPV prevalence between Danish women, where cervical cancer rates are extremely low, and Greenlandic women, where rates are nearly 4 times higher. Overall, the HPV rates were similar. However, in Greenland, HPV infections tended to be peak in women less than 19 years of age, followed by a dramatic drop in infection rates in their early 20s. HPV rates for Danish women were significantly lower in the first decades of life. The primary difference between the two groups was the age at initial onset of intercourse, indicating that exposure to HPV in a woman's teen years increases the risk ofthe eventual development ofcervical cancer.
Independent risk factors for the progression to cervical cancer include smoking, low income, and the use of oral contraceptives (Adam et aI., 2000) .
Nicotine, a potential carcinogen, is concentrated in the cervical tissue of women who smoke. Smoking also presumably lowers the immune response, increasing the likelihood of progressive damage. Sanjose et aI., (1996) confirmed the correlation between low-income level and a higher incidence of invasive cervical cancer. These researchers postulate that the difference is related to a lower use of preventive care, lack of appropriate screening, and a higher incidence ofHPV.
Kruger-Kjaer et aI., (1998) explored the relationship of long-term oral contraceptive (OC) use and the progression of dysplasia. In this study, they found correlation withOC use and the development of high-grade lesions; there was no relationship to the development of low-grade SIL. The estrogenized state of OC users may prevent the ectopy ofthe cervix from receding into the cervical canal, leaving the vulnerable area exposed.
Physical symptoms associated with cervical dysplasia are rare, but include complaints of vaginal itching, odor, swelling, or visible lesions. These symptoms may be related to other sexually transmitted diseases, such as chlamydia trachomatis, which may be present concomitantly. Concomitant sexually transmitted infections are another significant risk factor (Reed et aI., 1993; Schiffinan & Brinton, 1995; Koskela et aI., 2000) . Women or their male partners may present with visible condyloma, typically ofthe low-oncogenic risk type, most often types 6 and 11. However, often multiple HPV types are present, requiring further typing ifdiagnosed visually (Cothran & White, 1995) .
The most common clinical sign of actual cervical carcinoma is a visible lesion appearing as a tumor or ulceration. Women may present with irregular or excessive vaginal bleeding, post-coital spotting, and cervical ulceration. Bloody or purulent, odorous, non-pruritic discharge may appear, ifinvasive lesions are present. Late invasive symptoms may include bladder and rectal dysfunction or fistulas and pain in the lower pelvic region (MacKay, 1999) .
Differential Diagnosis-The Bethesda System
In an effort to clearly delineate the various possible cytological findings associated with the Pap smear, thus strengthening its value as a screening tool, a
1988 National Cancer Institute panel developed a standardized classification and diagnostic system known as the Bethesda System (Lunberg, 1988 ) (see Table 1 ).
This classification system, although modified in 1991, continues to provide a useful, standardized format for the differentiation of Pap smears and the accompanying clinical diagnosis (Kurman, Henson, Herbst, Noller, & Schiffinan, 1994) . The Bethesda System utilizes the following descriptive diagnoses: as to the type of malignancy (Lunberg, 1988) .
The Bethesda system also includes a statement as to the adequacy ofthe specimen, with a recommendation for repeating the smear if it is deemed unsatisfactory. A hormonal evaluation confirms ifthe hormonal pattern is compatible with the woman's age and history, requiring that the clinician provide this historical information to the pathologist.
The Bethesda system has led to greater clarity and differentiation ofthe diagnosis of Pap smears. However, since its inception, the number of equivocal Pap smears-the ASCUS category-has grown. The potential for morbidity associated with over-read Pap smears has led some to question the value of using the Pap smear as an end-stage screening tool (Jones, 1995) . Table 3 is an estimate ofthe costs for procedures related to cervical cancer screening and the time frame for receiving the results ofthese procedures.
Colposcopies typically are scheduled shortly after an irregular Pap smear is identified, meaning that the cost ofthe colposcopy is additive to that ofthe Pap smear. Therefore, slowing decisions while monitoring dysplasia with serial screening, rather than immediate colposcopic treatment, will often allow the body to heal itself and save money. The Thin-prep Pap method is significantly more expensive than the standard slide. This added cost is offset by the advantage of collecting the HPV sample at the same time as the Thin-prep. If the HPV sample is not needed, it may be discarded without further expense; if it is needed, a second collection fee will not be incurred. Forgoing annual screening in women who are at low-risk of cervical cancer would be an effective cost-control measure.
Patient Education and Preparation
Women need to understand that the Pap smear and HPV testing are screening tools used to identify pre-cancerous and cancerous cervical lesions. Table 4 is an information sheet, outlined in a question and answer format, designed to help women understand how best to prevent HPV contraction and how to prepare for screening tests and treatment procedures.
Treatment Plan
Invasive cervical cancer is a preventable disease. Advanced invasive cervical cancer has only a 14 % five-year survival rate (Worn: 1996); prevention is the key to effective treatment. The five-year survival rate is 99 % for women with localized cervical cancer, also known as cancer in situ (CIS). On average, carcinoma in situ will advance to invasive disease within two to ten years (MacKay, 1999) . This slow progression allows for identification and treatment before the cancer advances.
The method of treatment is dependent upon the results of cervical screening. Cervical intraepithelial neoplasia 1 (CIN 1) may be monitored for progression. These lesions often regress back to normalcy without treatment (Schiffinan & Brinton, 1995) . As the primary prognostic indicator of cervical carcinoma, a CIN 2 or 3 diagnosis requires colposcopic evaluation, and if abnormal cells are visualized, biopsy (Daley, 1998) .
Small, high-grade dysplastic lesions may be treated with ablative therapies, such as cauterization or cryotherapy (MacKay, 1999) . Visible lesions may also be excised using a wire loop, known as a "large loop excision". For this excision procedure to be successful, clear healthy margins surrounding the removed tissue must be present (Paraskevaidis et aI., 2000) . The treatment of choice for pre-invasive cancer, CIN 3 or carcinoma in situ, is complete surgical removal of the transformation zone, known as conization of the cervix. Ablative therapies must be followed with regular screening, especially the first 2 years after treatment, to quickly identify recurrence (MacKay, 1999) . Cancerous lesions that have extended past the pelvic wall (stages lIB, III, and IV) require radiation treatment (MacKay, 1999) .
Conclusion
Invasive cervical cancer is a needlessly deadly disease. Effective measures exist to prevent the unnecessary morbidity and mortality associated with cervical cancer. In developed countries, where established screening and treatment protocols exist, the incidence of cervical cancer has been dramatically reduced (Cuzick, 1998) . However, cervical cancer remains the leading cause of cancer death in women in most developing countries (Richart, 1995) . Even in the United States, a significant portion of the population is left unscreened or inadequately screened, leading to thousands of cervical cancer deaths each year (Cancer Statistics, 1998) .
Screening has historically centered upon the Papanicolaou smear.
However, Pap smear technology is not perfect. In a study of over 300 labs, nearly 20 % of women who were later found to have cervical pathology, originally had false-negative Pap smears (Montes et al., 1999) . 64.1 % (Manos et aI., 1999) 89.0% (Schiffman, 2000) Table 3 Cost 
What is human papillomavirus (HPV)?
Human papillomavirus is the virus that causes warts. To date, more than 68 different types of human papillomaviruses have been identified. Twenty-three different types ofHPV have been identified that infect the genital region ofmen and women. These various HPV types are associated with a range of genital diseases, from the common genital wart, condyloma, to invasive cancer ofthe cervix (Park et aI., 1995) .
How is genital HPV spread?
As with all warts, genital HPV is spread through direct skin-to-skin contact. It is not transmitted through blood or body fluids. Genital HPV targets the moist mucous membranes surrounding the genitals. The most common form oftransmission is direct contact between the infected skin on the penis, scrotum, vagina, vulva, or anus and the uninfected skin in the genital or anal region ofthe partner's body (ASHA, 1995 When should I have a Pap smear?
All women should begin having Pap screening when they become or are preparing to become sexually active. After the initial screen, you and your provider will need to determine the frequency offuture smears. Usually, yearly exams are recommended for three to four years, followed by screening every three to five years. Generally, women who have had a history of sexually transmitted infections should continue to have yearly screening. If abnormal cells are identified, more frequent screening, more in-depth testing to obtain a definitive diagnosis, or treatment may be necessary (Apgar & Brotzman, 1999 Can I prevent HPV?
Ifyou are sexually active, HPV can be difficult to prevent because it is often difficult to identify, and it is quite prevalent. HPV is contracted through body-to-body contact. Therefore, because a condom does not adequately cover the entire genital region, it is not an effective barrier to HPV. Use ofthe condom or the diaphragm may protect the cervix, because it is completely covered with these barrier methods. Obviously, condom usage remains extremely important as a tool for the prevention of most other sexually transmitted infections. The female condom, which covers the entire vulva, nlaY be more protective (Cothran & White, 1995) .
The best protection against HPV is to limit your number of sexual partners and to know your partner's sexual history. Women who begin sexual activity at an older age are statistically less likely to develop problems associated with HPV.
As the cervix matures, the vulnerable area becomes smaller.
Is there a cure for HPV?
No. It may be possible for your body's own immune system to clear the VIrUS. However, most often HPV is a virus that stays in your body once you have contracted it. Treatment can destroy the lesions, and for most women, the immune system will help keep the HPV under control. Over time, the chance of recurrent abnormalities from the HPV lessens.
Is there anything else that I can do to protect myself! Yes. The best protection is to keep your immune system as healthy as possible. This means not smoking, eating well, and protecting yourself against other sexually traIlSmitted infections by limiting your number of sexual partners and by using condoms. Women who smoke have a higher rate of cervical cancer;
smoking may inhibit the immune system, preventing or slowing repair of abnormal tissue. (2) Women who receive screening every 3-5 years are not at significantly greater risk for invasive cervical cancer than are women who are tested annually (Wolff: 1996; Richart, 1995) .
(3) High-grade SIL, CIN 2 or 3, is considered the only true precursor to cervical cancer (Adam et a!., 2000; Daley, 1998) .
(4) Testing of low-grade SIL and ASCUS Pap smears for HPV is a cost-effective and safe approach to avoid unnecessary colposcopic examinations (Apgar & Brotzman, 1999) .
(5) Positive HPV results will be identified through the use ofthe Digene Hybrid Capture II test. DNA recognition of any of 14 high-oncogenic risk types will be included as positive.
(6) Risk factors for HPV include onset of sexual activity as an adolescent, multiple partners, other sexually transmitted infections, smoking, low income, and the use of oral contraceptives (Adam et aI., 2000) .
